Skip to main content

Table 6 Incremental change in DAS28-ESR and DAS28-CRP at 12 months after LOT initiation

From: Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study

Antibody Status From 12 months
Abatacept Other bDMARD Incremental difference
Cohort (n) Mean 95% CI Cohort (n) Mean 95% CI LS Mean 95% CI P value
DAS28-ESR
 All patients 61 −1.98 −2.41,-1.55 113 −1.42 − 1.76,-1.08 − 0.56 − 1.04,-0.07 0.03
 ACPA+ 33 −1.84 −2.44,-1.23 46 −1.51 −2.05,-0.97 − 0.33 − 1.04,0.38 0.37
 ACPA- 11 −2.44 − 3.53,-1.35 24 −1.79 −2.71,-0.88 −0.64 − 1.70,0.41 0.23
 RF+ 42 −1.99 −2.51,-1.46 74 −1.43 −1.85,-1.01 −0.56 − 1.16,0.05 0.07
 RF- 14 −1.90 −2.88,-0.92 28 −1.77 −2.62,-0.93 −0.12 − 1.04,0.79 0.80
 ACPA+/RF+ 31 −1.83 −2.46,-1.21 42 −1.46 −2.02,-0.90 −0.37 −1.12,0.38 0.33
 ACPA+/RF- a −2.75 −28.19,22.70 a −1.46 −59.19,56.28 −1.29 −6.91,4.33 0.67
 ACPA−/RF+ a −2.21 −4.91,0.49 6 −0.91 −2.87,1.06 −1.30 −3.75,1.14 0.32
 ACPA−/RF- 9 −2.30 −3.41,-1.18 18 −1.89 −2.84,-0.94 −0.41 − 1.55,0.74 0.49
DAS28-CRP
 All patients 91 −1.86 −2.16,-1.56 90 −1.50 − 1.80,-1.19 −0.37 − 0.75,0.01 0.06
 ACPA+ 35 −1.79 −2.30,-1.28 33 −1.52 −2.07,-0.98 −0.26 −0.88,0.35 0.40
 ACPA- 9 − 1.85 −2.88,-0.83 16 −1.28 −2.10,-0.45 −0.58 − 1.79,0.64 0.36
 RF+ 65 −2.02 − 2.38,-1.67 57 −1.53 −1.92,-1.14 −0.49 −0.95,-0.03 0.04
 RF- 14 −1.58 −2.44,-0.72 21 −1.66 −2.42,−0.90 0.08 -0.90,1.07 0.87
 ACPA+/RF+ 33 −1.79 −2.29,-1.28 31 −1.39 − 1.93,-0.84 − 0.40 − 1.03,0.24 0.22
 ACPA+/RF- a −2.71 −13.76,8.35 a −2.73 −15.73,10.28 0.02 −3.62,3.66 0.99
 ACPA−/RF+ a −2.28 − 3.49,-1.08 a −1.26 −2.77,0.26 −1.03 − 2.60,0.55 0.23
 ACPA−/RF- a −1.23 −2.71,0.25 12 −1.15 −2.05,-0.24 −0.08 −1.74,1.57 0.92
  1. bDMARD Biologic disease-modifying antirheumatic drugs, CI Confidence interval, CRP c-reactive protein, DAS Disease activity score, ESR Erythrocyte sedimentation rate, n Is the number of patients with a DAS score recorded at LOT initiation and at 12 months
  2. aCells suppressed due to small numbers